IP Library Granted Patent US 9,192,718
Granted Patent B2
US 9,192,718 · App. 14/138,061 · Granted Nov 24, 2015

Nitric oxide therapies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,192,718
App. No.
14/138,061
Granted
Nov 24, 2015
Kind
B2
Abstract

A method for delivering nitric oxide therapy to a subject can include administering a composition including a nitric-oxide releasing agent and silica to the subject and releasing a therapeutic amount of nitric oxide from the composition.

Claims (13)

1. A nitric oxide delivery device comprising:

an inlet,

an outlet,

a particle filter at the outlet, wherein the particle filter includes two concentric annular filters with a surface-active material located between the two annular filters,

a chamber, and

a composition within the chamber including a nitric-oxide releasing agent, silica, and an antioxidant.

2. The nitric oxide delivery device of claim 1 , wherein the nitric-oxide releasing agent is polymeric composition including a polymer and at least one nitric oxide releasing N 2 O 2 − functional group.

3. The nitric oxide delivery device of claim 1 , wherein the antioxidant is ascorbic acid, alpha tocopherol, or gamma tocopherol.

4. The nitric oxide delivery device of claim 1 , wherein the nitric oxide agent is selected from the group consisting of X N(O)NO] and [N(O)NO X, wherein X is an organic or inorganic moiety.

5. The nitric oxide delivery device of claim 1 , wherein the composition further includes water.

6. The nitric oxide delivery device of claim 1 , wherein surface-active material is silica gel.

7. The nitric oxide delivery device of claim 1 , wherein the inlet, outlet and chamber each have a width, wherein the width is measured in a direction perpendicular to the longitudinal axis of the delivery device, and the width of the chamber is greater than the width of the inlet or outlet.

8. The nitric oxide delivery device of claim 1 , wherein the inlet, outlet and chamber are cylindrical, and the diameter of the chamber is greater than the diameter of the inlet or the diameter of the outlet.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2026
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: VERO BIOTECH INC.
Reel/Frame 075308/0198 →
SECURITY INTEREST Recorded Mar 16, 2026
From: VERO BIOTECH INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS COLLATERAL AGENT
Reel/Frame 075117/0935 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jan 3, 2024
From: RUNWAY GROWTH FINANCE CORP (F/K/A RUNWAY GROWTH CREDIT FUND INC.)
To: VERO BIOTECH INC. (F/K/A VERO BIOTECH LLC)
Reel/Frame 066186/0611 →
SECURITY INTEREST Recorded Jan 3, 2024
From: VERO BIOTECH INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 066187/0865 →
CHANGE OF NAME Recorded Feb 14, 2022
From: VERO BIOTECH LLC
To: VERO BIOTECH INC.
Reel/Frame 059085/0418 →
SECURITY INTEREST Recorded Dec 29, 2020
From: VERO BIOTECH LLC
To: RUNWAY GROWTH CREDIT FUND INC.
Reel/Frame 054866/0589 →
CHANGE OF NAME Recorded Jun 6, 2018
From: GENO LLC
To: VERO BIOTECH LLC
Reel/Frame 046304/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2015
From: FINE, DAVID H.
To: GENO LLC
Reel/Frame 035317/0563 →